Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist Cardiovascular Surgery Associates

Mark G. Davies, M.D., Ph.D. , M.B.A., F.A.C.S., F.R.C.S.I.

Dr. Mark Davies

Practice Location

6550 Fannin Street
Smith Tower Suite 1401
Houston, TX 77030


Education - Mark G. Davies, M.D., Ph.D. , M.B.A., F.A.C.S., F.R.C.S.I.

Medical School

  • Trinity College, Dublin, Ireland


  • Duke University, Durham, NC
  • General Surgery Residency, Royal College of Surgeons in Ireland, Dublin, Ireland


  • University of Washington, Seattle, WA

Areas of Excellence

  • Vascular Surgery
  • Arterial and Venous Endovascular Surgery
  • Aortic Endovascular Surgery
  • Carotid Stenting and Surgery
  • Acute Venous Disease
  • Signal Biology of Phospholipids
  • Protease Biology
  • Metabolic Syndrome
  • Outcomes of Endovascular Surgery
  • Gene and Molecular Therapy



Biography - Mark G. Davies, M.D., Ph.D. , M.B.A., F.A.C.S., F.R.C.S.I.

Mark G. Davies, MD, PhD, M.B.A. is Professor of Surgery in the Department of Cardiovascular Surgery, The Methodist DeBakey Heart and Vascular Center at The Methodist Hospital in Houston and Weill Cornell Medical College, New York. He is Program Director of the Vascular Residencies (5+2 and 0+5) and Director of the Vascular Ultrasound services within the Methodist Hospital. He is currently Vice-Chairman for Finance, Education, Administration and Research within Cardiovascular Surgery. Within the MDHVC, Dr. Davies supervises improvement projects in OR operations, supply chain management, clinical performance and patient care.

Dr. Davies has been very productive in both the basic science and clinic research arena through out his career and has published over 300 peer-reviewed articles on endovascular therapy and vascular biology.

His basic research interests are the study of the in vivo/in vitro cell signaling of vascular smooth muscle cells (with an emphasis on signal transduction in diabetes and metabolic syndrome) and pathobiology of intimal hyperplasia (with an emphasis on vein grafts). The three specific areas of research interest are: 1) the signal biology of phospholipids in vascular smooth muscle cells; 2) the study of signal transduction of plasminogen activators during cellular proliferation and migration of smooth muscle cells and during the development of intimal hyperplasia after arterial injury and vein grafting in murine models and 3) the signal biology of Metabolic Syndrome in the vasculature. He has completed a KO8 from the NIH and currently is funded through an RO1. His clinical Research interests are the study of the outcomes of endoluminal therapy for lower extremity disease with an emphasis on cost effectiveness, best practice and appropriate outcomes and he is presently spearheading the development of the Southern Vascular outcomes network to provide regional quality reporting and performance improvement for the south central United States.

Publications - Mark G. Davies, M.D., Ph.D. , M.B.A., F.A.C.S., F.R.C.S.I.

  1. Bakken AM, Protack CD, Roztocil E, Nicholl SM, Davies MG. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.  J Vasc Surg. 2009 May;49(5):1296-303.
  2. Protack CD, Bakken AM, Xu J, Saad WA, Lumsden AB, Davies MG. Metabolic syndrome: A predictor of adverse outcomes after carotid revascularization. J Vasc Surg. 2009 May;49(5):1172-80.e1; discussion 1180
  3. Davies MG, Saad WA, Bismuth JX, Peden EK, Naoum JJ, Lumsden AB.Outcomes of endoluminal reintervention for restenosis after percutaneous renal angioplasty and stenting. J Vasc Surg. 2009 Apr;49(4):946-52. Epub 2009 Feb 14
  4. Davies MG, Saad WE, Bismuth JX, Naoum JJ, Peden EK, Lumsden AB. Endovascular revascularization of renal artery stenosis in the solitary functioning kidney. J Vasc Surg. 2009 Apr;49(4):953-60. Epub 2009 Feb 14.
  5. Karmonik C, Bismuth JX, Davies MG, Lumsden AB. Computational hemodynamics in the human aorta: a computational fluid dynamics study of three cases with patient-specific geometries and inflow rates.  Technol Health Care. 2008;16(5):343-54.